Change the CAPTCHA code

sign up

Diagnosis and Treatment of NASH

The goal of this activity is to improve outcomes for patients with NASH by providing evidence-based education on the diagnosis and management of NASH and supporting the appropriate clinical adoption of newly approved therapies as they become available.

show all
Category: For physicians Family medicine Internal Medicine
Views: 67
Number: 4014
visibility 23 days to the end of the display (June 17 2018)
term set individually
New York, NY
z 100 spots
Sign up to reserve a place. Within 48 hours the presenter will contact you.
Name: Applied Clinical Education
Phone: 201-218-9656

Diagnosis and Treatment of NASH:
Evidence-Based Discussion of an Urgent Clinical Need

Release Date: December 6, 2017
Expiration Date: December 6, 2018

Based on a meeting held Monday, October 16, 2017 at the Orange County Convention Center in Orlando, Florida

Statement of Need

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease and a major health burden. The most aggressive subtype is nonalcoholic steatohepatitis (NASH), which can lead to fibrosis, cirrhosis, and the need for liver transplant. Despite an increasing prevalence in the United States due to an epidemic of obesity and diabetes, studies show that many clinicians are unfamiliar with NASH. Furthermore, the lack of an FDA-approved medication for NASH makes treatment challenging. This situation is expected to change in the near future, with several compounds currently in late-stage investigation.


The goal of this activity is to improve outcomes for patients with NASH by providing evidence-based education on the diagnosis and management of NASH and supporting the appropriate clinical adoption of newly approved therapies as they become available.

Intended Audience

Hepatologists and gastroenterologists who care for patients with NAFLD and NASH

Learning Objectives

After completing this activity, participants will be better prepared to:

  1. Describe the prevalence of and risk factors for NASH
  2. Describe the importance of early diagnosis in patients with NASH
  3. Apply the most recent guideline recommendations to the diagnosis and management of NASH
  4. Review the biological targets, efficacy, and safety of emerging pharmacotherapies for NASH

Method of Participation

To obtain credit, a score of 75% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. You must participate in the entire activity to receive credit. If you have any questions relating to the accreditation of this activity, please contact AKH at

Accreditation Statements


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Applied Clinical Education. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

The NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Zobair M. Younossi, MD, MPH
Chairman, Department of Medicine
Inova Fairfax Hospital
Vice President for Research
Inova Health System
Professor of Medicine
VCU-Inova Campus
Beatty Center for Integrated Research
Falls Church, Virginia

Ira Jacobson, MD
Director of Hepatology
NYU Langone Medical Center
New York, New York

Commercial Support

This activity is supported by an educational grant from Allergan, Inc.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

  • Zobair M. Younossi, MD, MPH: Allergan, Bristol-Myers Squibb, Gilead, Intercept (consultant); Janssen, Vertex (advisory board)
  • Ira Jacobson, MD: Genfit, Gilead, Merck (grant/research support); Gilead, Intercept, Merck (speakers’ bureaus); AbbVie, Bristol-Myers Squibb, Gilead, Intercept, Merck, Trek Therapeutics (consultant/advisor)
  • Dorothy Caputo, MA, BSN, RN, lead nurse planner, discloses no financial relationships with pharmaceutical or medical product manufacturers
  • AKH staff and planners have no relevant financial relationships to disclose
  • ACE staff and planners have no relevant financial relationships to disclose

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This course is designed solely to provide the health care professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the health care professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Supported by an educational grant from Allergan, Inc.

Jointly Provided by AKH Inc., Advancing Knowledge in Healthcare and Applied Clinical Education, in partnership with Art in CME


This event is neither sponsored by nor endorsed by ACG or WGO.

Terms Privacy Policy Advertise Contact us